How to Protect Yourself And Your Family From Dangerous Pharmacy Mistakes & Omissions


Prescription drug use is on the rise, with Mayo Clinic data revealing that over 70 percent of Americans currently take at least one prescribed drug. If you’re among today’s prescription-reliant majority, you likely receive strict instructions from your doctor regarding when and under what circumstances you can take your daily medications. Unfortunately, your efforts to remain safe could easily be compromised, as research from the Journal of Pharmacology suggests that issues at the pharmacy are responsible for 21 percent of medication errors. The prevalence of drug dispensing issues calls for increased vigilance. A few simple precautions could make all the…

Read More

FDA Warns of Dangers of Sirolimus (Rapamune) for Liver Transplant Patients | DC Metro Area Medical Malpractice Law Blog


Posted by: Salvatore J. Zambri, Esquire Recently, MedPage Today reported that “The FDA issued an alert regarding the risk of increased mortality in stable liver transplant patients who switch from a calcineurin inhibitor-based (CNI) immunosuppressive regimen to sirolimus (Rapamune).”  It was noted, however, “that a causal relationship has not been established” and that the FDA “is not recommending discontinuation of the drug, which is indicated for prevention of organ rejection in kidney transplant recipients older than 12.” The label for the drug “already carries a boxed warning of excess mortality and graft loss associated with the use of sirolimus in…

Read More

Atypical Antipsychotic Medications Effective But Risky for Children | DC Metro Area Medical Malpractice Law Blog


Posted by: Salvatore J. Zambri, Esquire According to the The Wall Street Journal, staff from the Food and Drug Administration (FDA) indicate that three medications “currently approved to treat bipolar disorder and schizophrenia in adults were effective at treating the disorders in children and adolescents, but carry significant risks.” As a result, the FDA is now “considering applications for AstraZeneca PLC’s Seroquel [quetiapine] and Eli Lilly and Co.’s Zyprexa [olanzapine] to treat bipolar disorder and schizophrenia in children and adolescents, and Pfizer, Inc.’s Geodon [ziprasidone] to treat bipolar disorder in children 10 to 17,” comments the report.  In fact, “an…

Read More

Propylthiouracil Poses Serious Liver Injury | DC Metro Area Medical Malpractice Law Blog


Posted by: Salvatore J. Zambri, Esquire An U.S. Department of Health and Human Services (HHS) report confirms that, two days ago, the U.S. Food and Drug Administration (FDA) “warned health care professionals about the risk of serious liver injury associated with the use of the anti-thyroid drug propylthiouracil for the treatment of Graves’ disease.” The FDA notification reported that an analysis of its Adverse Event Reporting System showed that there was an increased risk of hepatotoxicity. Importantly, comparing it to methimazole, a drug approved for the same purpose without the increased liver injury risk the FDA stated, “Health care professionals…

Read More

Antidepressants May Cause Breast Cancer | DC Metro Area Medical Malpractice Law Blog


Posted by: Salvatore J. Zambri, Esquire According to a recent Bloomberg report, researches have determined that certain antidepressants may increase the recurrence  of breast cancer among women who have already survived the disease.  The study reports that drugs including Prozac, Paxil and Zoloft “significantly decrease the effectiveness of a drug [tamoxifen] used to reduce the chances of breast cancer recurrence”, states the article. Notably, the study revealed that tumors were more than twice as likely to return after two years in women taking the antidepressants cited above while on the anti-cancer drug tamoxifen, as compared with those taking tamoxifen alone….

Read More

Taxotere Promotional Materials Misleading | DC Metro Area Medical Malpractice Law Blog


Posted by: Salvatore J. Zambri, Esquire Dow Jones Newswires  reports that the Food and Drug Administration (FDA) has urged Sanofi-Aventis SA, a drug manufacturer, “to stop distributing certain promotional material for its breast cancer drug, Taxotere [docetaxel], saying the material misleadingly claims the medicine is more effective than proven.”  According to the report, the FDA has indicated that “binders with reprinted medical studies claim Sanofi’s Taxotere is better than other medicines to treat patients with breast cancer after prior chemotherapy treatments failed,” yet the “FDA is unaware of substantial evidence to support these claims.” We encourage our readers to be…

Read More